This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Meridian Bioscience Granted Special 510(k) Clearance For TRU FLU® To Add Avian H7N9 Influenza A Virus Analytical Sensitivity Claim

Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the company’s TRU FLU ® assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU ® is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens.

New strains of Influenza viruses are continuously emerging to replace the more contemporary or common strains. The novel avian Influenza A strain H7N9 was first reported in China in March 2013. Since then, there have been 147 confirmed human cases of avian influenza A H7N9, with 47 deaths reported in China. It is important that rapid assays are able to detect novel strains as they emerge to enable physicians to deliver prophylaxis to and manage infected patients in a timely manner.

Meridian’s TRU FLU and TRU RSV ® products provide closed systems that limit the exposure of laboratory personnel to infectious agents in test samples during incubation and disposal.

John A. Kraeutler, Chief Executive Officer, stated, “Meridian is committed to providing accurate and rapid diagnostic solutions as novel flu strains emerge globally. During the 2009 H1N1 pandemic, Meridian received special 510(k) FDA clearance to add H1N1 analytical sensitivity claim for TRU FLU. Once again, Meridian knew that it was critically important to be prepared for a potential pandemic with the novel avian H7N9 strain to provide the best patient care.”

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded on NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs